A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00887341 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: tocilizumab [RoActemra/Actemra]
DRUG: tocilizumab [RoActemra/Actemra]

Sponsor

Hoffmann-La Roche